Angiogenic factors in blood serum of bone tumor patients.

It is proven that angiogenesis and cartilage resorption processes involving vascular endothelial growth factor (VEGF) and its receptors play an important role in bone tissue regeneration and bone tumor development. A comparative analysis of VEGE VEGF-R1, VEGF-R2 and angiogenin content in blood serum of healthy persons, and patients with primary malignant, benign and borderline bone tumors was performed. 366 bone tumor patients aged 14-76 years were examined; 223 (60,9%) male and 143 (39,1%) -female.

Expression of molecular markers in low-grade chondrosarcomas and cartilaginous tumors with uncertain differentiation.

Among the wide array of human neoplasms, primary tumors of bone are relatively uncommon and sundry group of solid tumors traditionally categorized according to their presumed mesenchymal differentiation. A locally aggressive or malignant group of cartilaginous matrix-producing neoplasms with diverse morphological features and clinical behavior require additional ancillary studies for prompt diagnosis and appropriate surgical treatment. They are histologically, behaviorally and genetically diverse, their pathogenesis is poorly understood Moreover treatment options are limited with surgical resection continuing to provide the only possibility of cure in many cases.

Associations of single nucleotide polymorphisms with malignant and borderline bone tumors.

Bone neoplasms - are a rare group of diseases, which ethiology and pathogenesis are not fully understood. We have studied 6 single nucleotide polymorphisms rs792/(GHI), rs7956547(IGFI), rs3761243(GNRH2), rs11737764(FGF2), rs6599400(FGFR3), and rs1690916(MDM2) associations with bone tumors. In our work we've detected significant associations with some single nucleotide polymorphisms: IGFl.

Expression of molecular markers in the tumor and survival prognosis in osteosarcoma.

Immunohistochemical study of p53, VEGF, Flt-1/VEGFR1 Ab-1, EGFR, HER-2/neu, Bax, and Cox-2 expression in osteosarcomas was carried out in 40 patients aged 16-70 years. Expression of p53 was detected in 27.5% tumors, VEGF in 15%, Flt-1/VEGFR1 Ab-1 in 97.